Rua Bioscience and PharmAla partner to supply MDMA in New Zealand

Rua Bioscience (NZX: RUA) and PharmAla Biotech (CSE: MDMA) have signed a distribution and licence agreement under which Rua will import, distribute and sell PharmAla's pharmaceutical-grade LaNeo MDMA capsules to authorised prescribers in New Zealand. The deal follows Medsafe's approval on 4 September 2026 of two psychiatrists to prescribe MDMA for post-traumatic stress disorder, making New Zealand only the second country after Australia to permit such prescriptions.

The first shipment will be supplied on a consignment basis, allowing Rua to enter the market with minimal upfront capital. Rua will supply the 40 mg LaNeo capsules, which are manufactured to good manufacturing practice (GMP) standards. Patient volumes are expected to be modest initially, with both parties describing the agreement as an early step in a broader regulatory shift.

A capital-light extension of Rua's model

Rua's existing business is built on the compliant supply of medical cannabis in New Zealand, and the company says the licences, quality systems and prescriber relationships it has developed in that category transfer directly to MDMA. Adding a second regulated medicine to its portfolio requires no significant additional infrastructure investment, which is consistent with what the company describes as its capital-light commercial strategy.

Paul Naske, chief executive of Rua Bioscience, said: "Medical cannabis taught us that safe, regulated access to new medicines starts with small, careful steps. Medsafe's decision on MDMA is one of those steps, and we're proud to help make it real for patients."

PharmAla positions itself as one of the first companies globally to manufacture GMP-grade MDMA at commercial scale. It already supplies clinical trials and authorised prescribers in Australia, where psychiatrists have been permitted to prescribe MDMA since 2023. The company's lead novel pipeline candidate, ALA-002, is a distinct MDXX-class molecule separate from the LaNeo product covered by this distribution deal.

Regulatory context and market landscape

The agreement arrives at a pivotal moment for psychedelic medicine as a category. Australia's 2023 decision to allow authorised psychiatrists to prescribe both MDMA and psilocybin was the first such regulatory move globally, and New Zealand has followed with its own approvals: psilocybin for treatment-resistant depression in 2025, and now MDMA for PTSD. Both frameworks share a common feature: access is tightly restricted to named, authorised clinicians rather than opened to general prescribing.

The regulatory picture elsewhere is more cautious. In the United States, the FDA declined to approve Lykos Therapeutics' MDMA-assisted therapy application in 2024, citing concerns about trial design and the difficulty of blinding in psychedelic studies. That decision has slowed US commercial momentum and shifted near-term market development toward jurisdictions with more permissive frameworks, including Australia and now New Zealand.

For PharmAla, the Rua deal replaces a prior New Zealand distribution agreement with Veridion Group, which was terminated by mutual consent on 1 September 2026. PharmAla confirmed that Veridion held no inventory, purchase orders or regulatory registrations at the time of termination, and that no payments were made by either party. The transition to Rua was therefore clean from a commercial standpoint.

Both companies will now work with Medsafe to complete the remaining regulatory and quality steps before the first shipment is released. Given the small number of currently authorised prescribers, revenue from this channel is unlikely to be material in the near term, but the agreement gives Rua an early-mover position in a category that could expand substantially if additional psychiatrists are approved and clinical evidence continues to accumulate.